Eli Lilly Launches Higher Dose Zepbound Vials at $150 Discount to Boost Demand

Eli Lilly has officially launched higher dose vials of its weight-loss drug Zepbound, priced $150 less than the existing auto-injector pen versions. This strategic move aims to stimulate demand for the medication amidst increasing competition in the weight-loss market.

Patients can now purchase 7.5 mg and 10 mg vials of Zepbound for $499 a month through the LillyDirect website, which is nearly 23% lower than the $650 charged for the injector pens for uninsured patients. The decision to offer these vials follows the introduction of lower dose options last August, which also saw their prices reduced by about $50 each, bringing their monthly costs to $349 and $499.

Patrik Jonsson, President of Cardiometabolic Health at Eli Lilly, noted that over 10% of patients have already opted for the vials since their launch. This initiative reflects Lilly's efforts to address sales declines and compete more effectively against Novo Nordisk's popular weight-loss drug Wegovy, which remains priced at $650 for uninsured patients.

While the new vials are still more expensive than compounded alternatives, which typically range from $231 to $330, the company is working to ensure compliance with FDA dosing regimens. Patients must refill their prescriptions within 45 days to maintain the lower pricing, or they may face costs of up to $699 for subsequent fills.

This launch underscores Eli Lilly's commitment to expanding access to its weight-loss treatments while navigating a challenging market landscape.